Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Drug Price Battle Now Bipartisan; Should Pharma Fret?

This article was originally published in Scrip

Executive Summary

Drug companies, particularly Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG, got a double punch from Capitol Hill on Nov. 4 when lawmakers from the House and the Senate upped their pressure on drug pricing – with a group of Democrats forming a new task force focused on combating "skyrocketing" costs of medicines and two senators turning the battle into a bipartisan fight by opening a new investigation and revealing plans for a hearing in December on the matter.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel